136 related articles for article (PubMed ID: 29264933)
1. Patient and prescriber characteristics among patients with type 2 diabetes mellitus continuing or discontinuing sulfonylureas following insulin initiation: data from a large commercial database.
Beachler DC; Fernandes G; Deshpande G; Jemison J; Lyons JG; Lanes S; Liu J; McNeill A
Curr Med Res Opin; 2018 Jun; 34(6):1061-1069. PubMed ID: 29264933
[TBL] [Abstract][Full Text] [Related]
2. Progression to insulin for patients with diabetes mellitus on dual oral antidiabetic therapy using the US Department of Defense Database.
Rascati K; Richards K; Lopez D; Cheng LI; Wilson J
Diabetes Obes Metab; 2013 Oct; 15(10):901-5. PubMed ID: 23531154
[TBL] [Abstract][Full Text] [Related]
3. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemia in type 2 diabetes: understanding patients' and physicians' knowledge and experience.
Fisher SJ; Huang X; Pawaskar M; Witt EA; Rajpathak S; Shankar RR; Inzucchi SE
Endocrine; 2018 Jun; 60(3):435-444. PubMed ID: 29460218
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
[TBL] [Abstract][Full Text] [Related]
6. A Safety Comparison of Metformin vs Sulfonylurea Initiation in Patients With Type 2 Diabetes and Chronic Kidney Disease: A Retrospective Cohort Study.
Whitlock RH; Hougen I; Komenda P; Rigatto C; Clemens KK; Tangri N
Mayo Clin Proc; 2020 Jan; 95(1):90-100. PubMed ID: 31902433
[TBL] [Abstract][Full Text] [Related]
7. Risk of hypoglycemia following intensification of metformin treatment with insulin versus sulfonylurea.
Roumie CL; Min JY; Greevy RA; Grijalva CG; Hung AM; Liu X; Elasy T; Griffin MR
CMAJ; 2016 Apr; 188(6):E104-E112. PubMed ID: 26811361
[TBL] [Abstract][Full Text] [Related]
8. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
9. Impact of hypoglycemic events and HbA1c level on sulfonylurea discontinuation and down-titration.
Laires PA; Tang J; Fan CP; Li Z; Qiu Y; Iglay K
Expert Rev Pharmacoecon Outcomes Res; 2017 Apr; 17(2):213-220. PubMed ID: 27345181
[TBL] [Abstract][Full Text] [Related]
10. Healthcare resource use and associated costs of hypoglycemia in patients with type 2 diabetes prescribed sulfonylureas.
Alemayehu B; Liu J; Rajpathak S; Engel SS
J Diabetes Complications; 2017 Nov; 31(11):1620-1623. PubMed ID: 28844830
[TBL] [Abstract][Full Text] [Related]
11. Effect of once-daily insulin detemir on oral antidiabetic drug (OAD) use in patients with type 2 diabetes.
Vora J; Caputo S; Damci T; Orozco-Beltran D; Pan C; Svendsen AL; Sølje KS; Khunti K;
J Clin Pharm Ther; 2014 Apr; 39(2):136-43. PubMed ID: 24329524
[TBL] [Abstract][Full Text] [Related]
12. Comparative Effectiveness of Insulin versus Combination Sulfonylurea and Insulin: a Cohort Study of Veterans with Type 2 Diabetes.
Min JY; Griffin MR; Hung AM; Grijalva CG; Greevy RA; Liu X; Elasy T; Roumie CL
J Gen Intern Med; 2016 Jun; 31(6):638-46. PubMed ID: 26921160
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of long-term adherence to and persistence with DPP-4 inhibitors in US adults with type 2 diabetes mellitus.
Farr AM; Sheehan JJ; Curkendall SM; Smith DM; Johnston SS; Kalsekar I
Adv Ther; 2014 Dec; 31(12):1287-305. PubMed ID: 25504156
[TBL] [Abstract][Full Text] [Related]
14. Trends in insulin initiation and treatment intensification among patients with type 2 diabetes.
Patrick AR; Fischer MA; Choudhry NK; Shrank WH; Seeger JD; Liu J; Avorn J; Polinski JM
J Gen Intern Med; 2014 Feb; 29(2):320-7. PubMed ID: 24101534
[TBL] [Abstract][Full Text] [Related]
15. Hypoglycemia, treatment discontinuation, and costs in patients with type 2 diabetes mellitus on oral antidiabetic drugs.
Bron M; Marynchenko M; Yang H; Yu AP; Wu EQ
Postgrad Med; 2012 Jan; 124(1):124-32. PubMed ID: 22314122
[TBL] [Abstract][Full Text] [Related]
16. Progression to insulin for patients with diabetes mellitus using the Texas Medicaid database.
Rascati KL; Richards KM; Lopez D; Cheng LI; Wilson JP
Clin Ther; 2011 Dec; 33(12):2016-20. PubMed ID: 22101160
[TBL] [Abstract][Full Text] [Related]
17. Risk factors associated with treatment discontinuation and down-titration in type 2 diabetes patients treated with sulfonylureas.
Iglay K; Qiu Y; Steve Fan CP; Li Z; Tang J; Laires P
Curr Med Res Opin; 2016 Sep; 32(9):1567-75. PubMed ID: 27175740
[TBL] [Abstract][Full Text] [Related]
18. Use of non-insulin diabetes medicines after insulin initiation: A retrospective cohort study.
Xu Y; Pilla SJ; Alexander GC; Murimi IB
PLoS One; 2019; 14(2):e0211820. PubMed ID: 30759121
[TBL] [Abstract][Full Text] [Related]
19. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes.
Janka HU; Plewe G; Riddle MC; Kliebe-Frisch C; Schweitzer MA; Yki-Järvinen H
Diabetes Care; 2005 Feb; 28(2):254-9. PubMed ID: 15677775
[TBL] [Abstract][Full Text] [Related]
20. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
